Trade Supernus - SUPN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.16 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 29.24 |
Open | 29.01 |
1-Year Change | -22.35% |
Day's Range | 29.01 - 29.78 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 25, 2024 | 29.24 | -0.72 | -2.40% | 29.96 | 30.05 | 29.07 |
Apr 24, 2024 | 30.22 | 1.52 | 5.30% | 28.70 | 30.33 | 28.70 |
Apr 23, 2024 | 29.91 | 0.61 | 2.08% | 29.30 | 30.16 | 29.30 |
Apr 22, 2024 | 29.67 | 1.06 | 3.70% | 28.61 | 30.23 | 28.61 |
Apr 19, 2024 | 29.37 | 0.74 | 2.58% | 28.63 | 29.48 | 28.58 |
Apr 18, 2024 | 28.83 | -0.02 | -0.07% | 28.85 | 29.39 | 28.55 |
Apr 17, 2024 | 28.96 | -0.43 | -1.46% | 29.39 | 30.00 | 28.85 |
Apr 16, 2024 | 29.40 | -0.30 | -1.01% | 29.70 | 30.29 | 29.30 |
Apr 15, 2024 | 29.95 | -0.05 | -0.17% | 30.00 | 30.45 | 29.63 |
Apr 12, 2024 | 30.20 | -1.22 | -3.88% | 31.42 | 31.69 | 30.01 |
Apr 11, 2024 | 31.96 | 0.16 | 0.50% | 31.80 | 32.51 | 31.58 |
Apr 10, 2024 | 31.76 | 0.85 | 2.75% | 30.91 | 31.87 | 30.26 |
Apr 9, 2024 | 31.69 | 0.78 | 2.52% | 30.91 | 32.30 | 30.59 |
Apr 8, 2024 | 31.40 | 0.91 | 2.98% | 30.49 | 32.97 | 30.49 |
Apr 5, 2024 | 33.52 | 0.56 | 1.70% | 32.96 | 33.54 | 32.96 |
Apr 4, 2024 | 33.17 | -0.90 | -2.64% | 34.07 | 34.40 | 33.03 |
Apr 3, 2024 | 33.79 | 1.04 | 3.18% | 32.75 | 34.01 | 32.70 |
Apr 2, 2024 | 33.11 | 0.04 | 0.12% | 33.07 | 33.50 | 32.65 |
Apr 1, 2024 | 33.48 | -0.49 | -1.44% | 33.97 | 33.97 | 33.05 |
Mar 28, 2024 | 34.04 | 0.33 | 0.98% | 33.71 | 34.31 | 33.34 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Supernus Company profile
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).
Equity composition
Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA
Industry: | Proprietary & Advanced Pharmaceuticals |
9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com